Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Phase 2 Unknown 55 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

This study is a multi-center, Single-arm Phase II study to evaluate the clinical efficacy and safety of Consolidation HLX10 (Serplulimab) Following Hypofractionated Radiotherapy With Concurrent Chemotherapy for Patients With Limited Stage Small Cell Lung Cancer

Timeline

Start: 2022-09-23
Primary completion: 2024-06-30
Completion: 2025-06-30

Publications

Wu Y, Deng L, Wang J, Zhang T, Cao J, Zhou X, Duan J, Bi N. Single-arm phase II study of consolidation serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small-cell lung cancer: ASTRUM-LC01 study protocol. BMJ Open. 2025 May 21;15(5):e085552. doi: 10.1136/bmjopen-2024-085552.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Serplulimab	Monoclonal antibody	300 mg	Intravenous

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Summary

Timeline

Publications

Drugs

Indications